Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 5/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 9/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27790235 | 0.76 | RPS6KA5 (0.39) | RPS6KA5RPS6KA4EGFRCYP11B1CYP11B2 | |
| SCHEMBL22516864 | 0.75 | CYP1A2 (0.39) | CASP1CASP7HSD17B10CYP1A2DHFR | |
| SCHEMBL23519529 | 0.73 | KDM4E (0.35) | CASP1CASP7HSD17B10DHFRALDH1A1 | |
| SCHEMBL23097832 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL20223112 | 0.71 | BRPF1 (0.40) | CASP1CASP7HSD17B10RPS6KA5RPS6KA4 | |
| SCHEMBL30473131 | 0.71 | BRPF1 (0.40) | CASP1CASP7HSD17B10RPS6KA5RPS6KA4 | |
| SCHEMBL35211521 | 0.70 | MAPK1 (0.35) | HSD17B10CYP1A2CYP3A4TSHRCLK4 | |
| SCHEMBL5438186 | 0.69 | RPS6KA5 (0.44) | CASP1CASP7HSD17B10RPS6KA5CYP1A2 | |
| SCHEMBL10151403 | 0.69 | MKNK2 (0.41) | HSD17B10EGFRCYP1A2CYP3A4TSHR | |
| SCHEMBL2628318 | 0.69 | RPS6KA5 (0.32) | RPS6KA5RPS6KA4CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
| WO-2017201187-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | CASP1 2181/4885CASP7 3144/4885HSD17B10 54/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | CASP1 2049/4885CASP7 3595/4885HSD17B10 32/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | CASP1 2695/4885CASP7 3854/4885HSD17B10 20/4885 |
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | CASP1 2268/4885CASP7 2484/4885HSD17B10 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.